(RTTNews) - MorphoSys AG (MOR) Tuesday said the primary endpoint was met of a real-world data study demonstrating clinical superiority of the combination of tafasitamab and lenalidomide compared to lenalidomide alone.
According to the company, the study collected data from 490 non-transplant eligible patients with relapsed/ refractory diffuse large B cell lymphoma who had received lenalidomide monotherapy in the U.S. and the EU in a real-world setting.
As a result, 76 eligible patients were identified and matched 1:1 to 76 of 80 L-MIND patients based on important baseline characteristics.
The primary endpoint of the study has been met and shows a statistically significant superior best ORR of the tafasitamab/lenalidomide combination compared to lenalidomide monotherapy.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
